Streetwise Management Q&As


Brett Earl

Medical Use of Nitric Oxide Expands as Costs Come Down
Source: Streetwise Reports  (9/19/18)
Dr. Brett Earl, a practicing physician and a vice president and director of Nu-Med Plus, discusses the many uses of nitric oxide and Nu-Med Plus' unique, low-cost delivery system. More >


Cancer in the Crosshairs: IMV Looks to Deliver Immunotherapy a New Way
Source: Streetwise Reports  (5/16/18)
In this interview with The Life Sciences Report, IMV Inc.'s CEO Fred Ors and Pierre Labbè, chief financial officer, describe the innovative immunotherapy platform technology that has attracted partnerships with big pharma, prompted reorganization of the company, and holds long-term promise for cancer patients. More >


Biotech Advances Treatments for Liver Disease, Pain, Mental Illness
Source: Streetwise Reports  (3/22/18)
With a pipeline expected to generate news flow throughout 2018, this company anticipates a productive 2018.
More >


Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports  (10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >


J. Joseph Kim

Inovio Moves Forward on Brain Cancer and Cancers Caused by HPV; Zika and Ebola Vaccines Also Advance
Source: The Life Sciences Report  (5/17/17)
Inovio Pharmaceuticals' pipeline of vaccine and immunotherapeutic products is advancing steadily through the phases of development, with a host of milestones anticipated in 2017, including the start of a Phase 3 trial in cervical dysplasia and the initiation of trials with partners in brain cancer and cancers caused by human papillomavirus. In this interview with The Life Sciences Report, Inovio President and CEO, Dr. J. Joseph Kim, walks investors through the promising possibilities, and also provides updates on its vaccines for the Zika, MERS and Ebola viruses. More >


Kevin Little

3D Signatures' Platform Taps into the Power of the Genome
Source: The Life Sciences Report  (5/10/17)
How fast is my cancer progressing? Does this treatment present my best option for a cure? These two big questions, which determine outcomes for patients with serious diseases such as Hodgkin's lymphoma, prostate cancer and Alzheimer's disease, are addressed by the platform technology in development by 3D Signatures Inc. In this interview with The Life Sciences Report, 3DS's new Chief Scientific Officer, Dr. Kevin Little, describes the TeloView platform, its utility in the marketplace and what makes it a compelling investment. More >


Elliot Goldstein

The ProMIS of an Alzheimer's Cure
Source: The Life Sciences Report  (5/3/17)
With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.
More >


Jim Brown

Many Paths to Success with DURECT's Pipeline
Source: Dr. James Brown for The Life Sciences Report  (3/29/17)
DURECT has a pipeline of drugs for a wide range of indications, from NASH to psoriasis to postoperative pain. In this interview with The Life Sciences Report, Dr. James Brown, DURECT's President and CEO, discusses the potentially groundbreaking epigenetic regulator DUR-928, POSIMIR's late-stage testing for postoperative pain and an abuse-deterrent oral technology. More >


RXi-MirImmune Merger Aims to Unlock Value Through Groundbreaking Technology
Source: The Life Sciences Report  (2/22/17)
RXi Pharmaceuticals' proprietary self-delivering RNAi (sd-rxRNA) platform offers efficient delivery to cells ex vivo, an application with tremendous potential in immuno-oncology. It's no surprise then that RXi has acquired MirImmune, a company that has been focusing on the next generation of immunotherapies for the treatment of cancer. In this interview with The Life Sciences Report, Geert Cauwenbergh, RXi's President and CEO; Alexey Eliseev, Chief Business Officer; and Pam Pavco, Chief Development Officer, discuss their technologies, the merger and why they believe that in 10 years pure chemotherapy could be relegated to the treatment of last resort. More >


Radioimmunotherapy 2.0: Actinium Sets Eyes on Bone Marrow Transplant and AML with Later-Stage Programs
Source: The Life Sciences Report  (8/17/16)
Radioimmunotherapy is experiencing a renaissance, and Actinium Pharmaceuticals Inc. is in position to benefit, according to company executive chairman Sandesh Seth. With two assets targeting treatment of AML in older adults in clinical trials, and a platform primed to "nuke cancer," the company has a number of milestones in its near future that investors should be watching. More >


Punit Dhillon

OncoSec Delivers Cancer Therapy Straight to the Tumor
Source: Special to The Life Sciences Report  (6/1/16)
Cancer patients often receive multiple rounds of chemotherapy, with new drugs incorporated into treatment programs as tumors develop resistance. OncoSec Medical Incorporated's Punit Dhillon describes how his company is challenging that paradigm with a proprietary platform that delivers therapeutic agents directly to the tumor, while also laying a foundation for expanded use of combination immunotherapies at the forefront of cancer treatment. More >


Kolin Ozonian

How Nobilis Health Will Break Out of the Healthcare Payment Mold
Source: George S. Mack of The Life Sciences Report   (5/25/16)
Managing both acquisitions and internal growth at the same time is difficult for most small companies, akin to drinking water and singing at the same time. Not so for Nobilis Health Corp., which is orchestrating the flow of new patients to its ambulatory surgical centers while it adds an ensemble of new clinics, resulting in harmonious revenue. The conductor is merger-and-acquisition specialist Kolin Ozonian, who brings years of business development experience in large-cap healthcare to this small-cap enterprise. In this interview with The Life Sciences Report, Ozonian discusses his company's newest technology and talks about how Nobilis will achieve critical mass. More >


Domenic Della Penna

Dialing Back Euphoria: The Intellipharmaceutics Prescription for Opioid Abuse
Source: Special to The Life Sciences Report  (5/11/16)
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications. More >


James Joyce

Exosome Sciences Uncovers Biomarker Candidate to ID Players with CTE
Source: Special to The Life Sciences Report  (5/4/16)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc., is developing an exosome-based platform to diagnose a broad-spectrum of disease conditions. In this interview with The Life Sciences Report, Executive Chairman James "Jim" Joyce shares the initial clinical results of a biomarker study to diagnose chronic traumatic encephalopathy (CTE), a neurodegenerative disorder often found in professional football players through postmortem autopsy. Mr. Joyce reports on the discovery of a TauSome™ biomarker found to be 9x higher, on average, in former National Football League players as compared to control subjects. Exosome Sciences believes its TauSome test may be the first noninvasive candidate to diagnose CTE in living individuals. More >


Christopher Schaber

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
Source: Special to The Life Sciences Report  (4/27/16)
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. More >


Michael Becker

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
Source: Special to The Life Sciences Report  (4/20/16)
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
More >


Frank Oakes

Stellar Biotechnologies: Cures for Cancer, Alzheimer's Disease, Lupus, and More Underscore the Critical Need to Protect Oceans
Source: Staff of The Life Sciences Report  (4/5/16)
Frank Oakes, the chairman, president and CEO of Stellar Biotechnologies, has a passion for the potential life-saving cures the ocean may provide. His company, a world leader in the production of sustainable, scalable and fully traceable GMP-grade KLH protein, has established research and manufacturing facilities along the Pacific Ocean to produce KLH, and Oakes himself has more than three decades of management experience in aquaculture. In this interview with The Life Sciences Report, Oakes talks about how he got involved in this exciting and emerging space, and describes the potential Stellar KLH has in the burgeoning field of immunotherapy. More >


David Kalergis

Diffusion Pharmaceuticals Takes Aim at Brain Cancer: CEO David Kalergis
Source: George S. Mack of The Life Sciences Report  (3/30/16)
It takes extraordinary dexterity to execute a strategic merger, and then to take first steps toward positioning a new molecular entity for a Phase 3 drug trial and potential partnership with a big pharma. That's exactly the inflection point at which Diffusion Pharmaceuticals Inc. finds itself, says CEO David Kalergis. In this interview with The Life Sciences Report, Kalergis lays out Diffusion's plan for pivotal development of its treatment for primary brain cancer, which could drive the company's market cap to valuations that would bring huge upside to investors if successful. More >


Lisa Crossley

Moseda Joins Telus and Apple in the $20B Patient Home Monitoring Sector
Source: Special to The Life Sciences Report  (3/29/16)
Because chronic conditions are difficult to manage by patients at home, with complications, hospitalizations and other expensive interventions sometimes necessary, they account for more than 75% of healthcare costs worldwide. To meet this need, Moseda Technologies has developed innovative, secure mobile software solutions for the $20 billion community/home care market. In this interview with The Life Sciences Report, Moseda's CEO, Dr. Lisa Crossley, describes the company's comprehensive hardware and software solution, dubbed CareKit, which allows patients to receive high-quality care in the home, improving health outcomes and enhancing quality of life for patients and families while reducing the cost of care. More >


Kolin Ozonian

Nobilis Health Doubles Down, Offering Organic Growth and Aggressive Acquisitions: Kolin Ozonian
Source: George S. Mack of The Life Sciences Report  (3/23/16)
Businesses can grow in two ways—internally and externally. Nobilis Health Corp. has a voracious appetite for both. The company is a development and management firm that acquires private outpatient surgical centers—in short, it's a business model built on efficiencies. Nobilis scans the market for clinics that can be acquired and scaled up using sophisticated direct marketing approaches. In this interview with The Life Sciences Report, Nobilis' mergers-and-acquisitions specialist Kolin Ozonian talks about the business model and tells investors how he and the Nobilis team plan to aggressively grow the company. More >


CorMedix Transformative Anti-Infective Technology for Catheters Developed to Decrease Serious Drug-Resistant Infections: CEO Randy Milby
Source: George S. Mack of The Life Sciences Report  (2/11/16)
Patients on dialysis and cancer patients with indwelling catheters live with the possibility of contracting drug-resistant infections that can become more life threatening than their primary diseases. CorMedix Inc. (CRMD:NYSE.MKT) is developing a platform that has shown impressive results in preventing serious bloodstream infections. In this interview with The Life Sciences Report, CorMedix CEO Randy Milby addresses his company's science, pipeline and market opportunity. Chief Scientific Officer and Cofounder Antony Pfaffle, an internist who practiced nephrology, joins the conversation to relate his experience managing chronically ill patients undergoing catheter-based therapies in the critical care setting. More >


Stewart Washer

Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics
Source: Peter Byrne of The Life Sciences Report  (2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver. More >


Leo Ehrlich

A Small-Cap Biotech with Big Ideas for Acute Infections and Cancers: Cellceutix's Leo Ehrlich and Dr. Daniel Jorgensen
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Drug development seems to move at a snail's pace, but Cellceutix Corp.'s CEO Leo Ehrlich says his company has jumped through the most time-consuming hoops of development and now has a diversified pipeline with three main drug candidates, any of which could become the lead program with new data in 2016. Ehrlich and Chief Medical Officer Dr. Daniel Jorgensen, an infectious disease specialist, discuss the candidates, beginning with the first new class of antibiotics to enter Phase 3 in skin infections in decades. More >


Jim Brown

Making Old Drugs New Again with Specialized Biotech: DURECT Corp.'s James E. Brown
Source: George S. Mack of The Life Sciences Report  (1/27/16)
Sometimes wonderful ideas live on and create value for the ages. Alza Corp. was a pioneer in the field of drug delivery, and that illustrious heritage continues in its spinout, DURECT Corp., which has leveraged the technology to enable highly innovative, value-added products that may soon be on the market. In this interview with The Life Sciences Report, DURECT cofounder and CEO James E. Brown discusses his company's pipeline, and how DURECT is evolving into a high-margin, blockbuster biotech. More >


James Joyce

Aethlon Medical CEO Jim Joyce Discusses the Forthcoming 'Concussion' Movie and CTE Research Being Conducted by Aethlon's Exosome Sciences Subsidiary
Source: Gail Dutton of The Life Sciences Report  (12/22/15)
Exosome Sciences, a majority-owned subsidiary of Aethlon Medical Inc. (AEMD:NASDAQ), is pioneering the potential use of an exosome-based biomarker to diagnose chronic traumatic encephalopathy (CTE), a condition that otherwise can only be identified postmortem. As James "Jim" Joyce, executive chairman, tells The Life Sciences Report, other companies are exploring this approach in oncology, but Exosome Sciences is the only company advancing an exosome-based candidate to diagnose CTE. More >


Showing Results: 1 to 25 of 59 Next

Notable Quotes

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts